A Patient With Novel PPP1CB -ALK Fusion Advanced NSCLC Achieved Long Survival From Alectinib: A Case Report.

ALK gene fusions are well-established oncogenic drivers that occur in approximately 5% of NSCLCs. The EML4 gene is the most frequent fusion partner. With the advent of next-generation sequencing, numerous novel ALK fusions have been discovered; however, many have not been represented in pivotal clinical trials evaluating ALK tyrosine kinase inhibitors. We present a case of advanced NSCLC with a rare PPP1CB-ALK fusion. The patient achieved a durable response to alectinib, with a progression-free survival of nearly four years, and the patient continues to be progression free at the most recent follow-up. This case expands the spectrum of ALK fusion partners in NSCLC and contributes additional clinical evidence supporting the efficacy of alectinib therapy in rare ALK fusions.